Revelation Biosciences Inc (REVB) - Total Liabilities
Based on the latest financial reports, Revelation Biosciences Inc (REVB) has total liabilities worth $1.85 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Revelation Biosciences Inc (REVB) cash conversion ratio to assess how effectively this company generates cash.
Revelation Biosciences Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Revelation Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Check REVB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Revelation Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Revelation Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Timah Resources Ltd
AU:TML
|
Australia | AU$10.26 Million |
|
Eastern Resources Ltd
AU:EFE
|
Australia | AU$217.98K |
|
Rocky Mountain Liquor Inc
V:RUM
|
Canada | CA$12.55 Million |
|
Damon Inc. Common Stock
NASDAQ:DMN
|
USA | $29.17 Million |
|
Next 15 Group PLC
LSE:NFG
|
UK | GBX400.67 Million |
|
Netcapital Inc
NASDAQ:NCPL
|
USA | $4.00 Million |
|
Mid Wynd International Investment Trust plc
LSE:MWY
|
UK | GBX705.00K |
|
NetJobs Group AB
ST:NJOB
|
Sweden | Skr758.00K |
Liability Composition Analysis (2016–2024)
This chart breaks down Revelation Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see REVB market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Revelation Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Revelation Biosciences Inc (2016–2024)
The table below shows the annual total liabilities of Revelation Biosciences Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.91 Million | -65.61% |
| 2023-12-31 | $5.56 Million | +25.03% |
| 2022-12-31 | $4.45 Million | +107.83% |
| 2021-12-31 | $2.14 Million | +77.18% |
| 2020-12-31 | $1.21 Million | +4494.53% |
| 2019-12-31 | $26.31K | -100.00% |
| 2018-12-31 | $2.19 Billion | +14.64% |
| 2017-12-31 | $1.91 Billion | +10.72% |
| 2016-12-31 | $1.73 Billion | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treat… Read more